Massivemarkets

SRNE

SORRENTO THERAPEUTICS INC

OTC Link · USD

—+0.00 (+0.00%)
As of 3:54:17 PM EST on Nov 16, 2026 · 15-minute delayed

Stock performance

How SORRENTO THERAPEUTICS INC (SRNE) stock has performed from one day to one year, with its 52-week range.

+0.00%
+$0.00 over 1D
-$0.06-$0.02$0.02$0.069:30 AM11:20 AM12:35 PM2:20 PM8:00 PM$0.00
1D
+0.00%
1W
+0.00%
1M
-40.00%
YTD
-88.46%
1Y
-94.55%
52-wk range
$0.00 – $0.01

Key statistics

Today's trading snapshot for SRNE: day range, open, previous close, volume and market cap.

Day range
—
Open
—
Prev close
$0.00
Volume
0
Market cap
—
Shares out
—

8-K filings

Material corporate events SORRENTO THERAPEUTICS INC has disclosed to the SEC on Form 8-K.

  • on February 13, 2023, Sorrento Therapeutics, Inc. ('Sorrento' or the 'Company') and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (together with the Company, the 'Debtors'), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas

  • the staff of Nasdaq had determined that the Company's common stock will be delisted from Nasdaq. The Delisting Notice indicated that trading of the Company's common stock will be suspended at the opening of business on February 23, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's common stock from listing and registration on Nasdaq.

  • Material litigationFeb 13, 2023

    On December 2, 2022, the arbitrator in that arbitration issued an award (the 'Antibody Award') granting contractual damages and pre-award interest in the amounts of $156,829,562 to NantCell and $16,681,521 to NANTibody. On February 7, 2023, the Court granted the Nant Entities' petitions, entered judgment upon the Antibody Award, and ordered Sorrento to pay to the Nant Entities the previously disclosed amounts awarded in the Antibody Award.

  • Material litigationFeb 13, 2023

    In April 2019, the Company filed an action in the Los Angeles Superior Court derivatively on behalf of Immunotherapy NANTibody LLC against NantCell, Inc. and Patrick Soon-Shiong, among others, related to several breaches of the June 11, 2015 Limited Liability Company Agreement. The suit alleges breaches of fiduciary duties and seeks restoration of $90.05 million to the NANTibody capital account.

  • On February 13, 2023, Sorrento Therapeutics, Inc. (the "Company") and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the "Chapter 11 Filings").

Dividend history and stock splits

SORRENTO THERAPEUTICS INC's recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 1-for-25Aug 1, 2013

SRNE short interest

How heavily SRNE is shorted: shares short, days to cover and average daily volume.

Days to cover
29.6
Short interest
3.5M
Avg volume
118.19K

As of · reported to FINRA twice monthly.

SRNE news

The latest news and headlines about SORRENTO THERAPEUTICS INC (SRNE).

Frequently asked questions

What is the SORRENTO THERAPEUTICS INC (SRNE) stock price today?

Massive provides real-time and historical SORRENTO THERAPEUTICS INC (SRNE) quotes via REST API, WebSocket and MCP.

What is SORRENTO THERAPEUTICS INC?

SORRENTO THERAPEUTICS INC

What is the short interest in SRNE?

As of Oct 30, 2026, SRNE has 3.5M shares short and 29.6 days to cover.

What exchange is SRNE listed on?

SORRENTO THERAPEUTICS INC (SRNE) trades on OTC Link in USD.

Build with AI

Build an analysis of SRNE with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a SRNE analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.